This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagaoka, H. Articles by Katori, M. Search for Related Content PubMed PubMed Citation Articles by Nagaoka, H. Articles by Katori, M.

Circulation, Vol 52, 325-332, Copyright © 1975 by American Heart Association

ARTICLES

Inhibition of kinin formation by a kallikrein inhibitor during extracorporeal circulation in open-heart surgery

H Nagaoka and M Katori

Involvement of the kinin system was studied in 58 patients during extracorporeal circulation in open heart surgery. At the onset of extracorporeal circulation, there was no increase of free kinin in blood and no reduction of plasma kininogen, when the latter was expressed as mug bradykinin/mg plasma protein. With the lapse of time, kinin in the blood increased significantly, and decrease of kininogen was also significant. The longer the circulation time, the greater the consumption of kininogen. The site of the kinin formation was presumed to be the heart-lung machine since the level of kinin increased slightly and kininogen decreased gradually in the blood leaving the machine, compared with those levels entering the machine. The difference in kininogen was significantly different from zero at termination of extracorporeal circulation. Administration of a kallikrein-trypsin inhibitor, trasylol (A. G. Bayer), infused into the heart-lung machine, prevented the decrease of kininogen. Reduction of the total peripheral resistance during this circulation was also prevented. The hemoconcentration, presumably the result of vascular permeability increase caused by increased kinin, was prevented by trasylol in cases in which extracorporeal circulation lasted over 60 minutes. Trasylol applied thus appears to be an effective counteragent for circulatory disturbances which occur during extracorporeal circulation.

This article has been cited by other articles:

				P. J. Hess Jr. Systemic inflammatory response to coronary artery bypass graft surgery Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S6 - S9. [Abstract] [Full Text] [PDF]

				V. R. Conti and C. McQuitty Vasodilation and Cardiopulmonary Bypass : The Role of Bradykinin and the Pulmonary Vascular Endothelium Chest, December 1, 2001; 120(6): 1759 - 1761. [Full Text] [PDF]

				M. Cugno, J. Nussberger, P. Biglioli, F. Alamanni, R. Coppola, and A. Agostoni Increase of Bradykinin in Plasma of Patients Undergoing Cardiopulmonary Bypass : The Importance of Lung Exclusion Chest, December 1, 2001; 120(6): 1776 - 1782. [Abstract] [Full Text] [PDF]

				C. F. Mojcik and J. H. Levy Aprotinin and the systemic inflammatory response after cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2001; 71(2): 745 - 754. [Abstract] [Full Text] [PDF]

				C. R. Smith and T. B. Spanier Aprotinin in deep hypothermic circulatory arrest Ann. Thorac. Surg., July 1, 1999; 68(1): 278 - 286. [Abstract] [Full Text] [PDF]

				M. Ehrlich, M. Grabenwoger, F. Cartes-Zumelzu, D. Luckner, J. Kovarik, G. Laufer, A. Kocher, R. Konetschny, E. Wolner, and M. Havel Operations on the thoracic aorta and hypothermic circulatory arrest: Is aprotinin safe? J. Thorac. Cardiovasc. Surg., January 1, 1998; 115(1): 220 - 224. [Abstract] [Full Text] [PDF]

				M. Ali, J. Becket, J. Brannan, J. Fleming, and K. Taylor The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass Perfusion, May 1, 1996; 11(3): 278 - 280. [PDF]